-
3 weeks ago | 
insideprecisionmedicine.com | Larissa Warneck-Silvestrin |Larissa Warneck
Scientists at the Gray Faculty of Medical and Health Sciences at Tel Aviv University in Israel have discovered that neutrophils, a type of immune cell, play an important role in breast cancer tumor progression. These findings, say the researchers, could make neutrophils important drug targets and biomarkers for advanced breast cancer. In 2022, there were an estimated 2.3 million new breast cancer cases, and approximately 670,000 deaths resulted from female breast cancer.
-
1 month ago | 
insideprecisionmedicine.com | Larissa Warneck
Researchers at the University of Texas MD Anderson Cancer Center in Houston, Texas, have identified a new biomarker called TTF-1 that can help physicians predict the outcome for patients with a specific type of non-small cell lung cancer (NSCLC). Patients with KRAS G12C-mutated NSCLC and high expression of TTF-1 had better chances of survival upon being treated with the KRAS inhibitor sotorasib, while patients with tumors that express low TTF-1 levels responded poorly to the treatment.
-
1 month ago | 
insideprecisionmedicine.com | Larissa Warneck
Researchers at the Francis Crick Institute and the Gulbenkian Institute for Molecular Medicine (GIMM) have discovered that a family of proteins called FIKK kinases, found in the deadliest malaria-causing parasite, Plasmodium falciparum, could be a promising new target for treating malaria. Malaria is a life-threatening disease caused by a parasite that is transmitted to humans by some mosquitoes.
-
1 month ago | 
insideprecisionmedicine.com | Larissa Warneck-Silvestrin |Larissa Warneck
Researchers at the Sydney Brenner Institute for Molecular Bioscience (SBIMB) at the University of the Witwatersrand in Johannesburg, South Africa, have discovered two genetic variants that can be linked to breast cancer in black South African women.
-
1 month ago | 
insideprecisionmedicine.com | Larissa Warneck-Silvestrin |Larissa Warneck
GLP-1RAs, first-generation weight-loss medications, such as liraglutide—known by the brand names Victoza and Saxenda—and exenatide—marketed under the names Byetta and Bydureon—seem to have anti-cancer benefits beyond weight loss, compared to weight loss surgery. This new study was led by researchers of Clalit Health Services in Tel Aviv, Israel, and the Hasharon Hospital, Rabin Medical Center in Petah Tikva, Israel.
-
Nov 22, 2024 | 
insideprecisionmedicine.com | Larissa Warneck-Silvestrin |Larissa Warneck
Researchers at Fudan University in Shanghai, China, have created an atlas of the human plasma proteome based on data from over 53,000 adults. This data can enable precision medicine by helping researchers understand which proteins are linked to diseases and which are health-related. The study was recently published in the journal Cell. Using data from the UK Biobank, the researchers associated 2,920 plasma proteins with 406 prevalent diseases, 660 incident diseases, and 986 health-related traits.
-
Nov 21, 2024 | 
insideprecisionmedicine.com | Larissa Warneck-Silvestrin |Larissa Warneck
The field of molecular diagnostics—also known as molecular pathology—is experiencing a period of rapid growth. In 2023, the global molecular diagnostics market size was valued at around $15.4 billion, reaching an estimated $17.3 billion in 2024, and is expected to grow at a CAGR of 13.5% by 2029 to reach $32.7 billion.
-
Nov 13, 2024 | 
insideprecisionmedicine.com | Larissa Warneck-Silvestrin |Larissa Warneck
Researchers at the Georgia Institute of Technology have developed lab-grown models of the human immune system that can be used to understand why some cancer patients are more susceptible to frequent infections even years after completing cancer treatment. Known as human immune organoids, these miniature models of the human immune system address two key challenges for researchers and patients.
-
May 29, 2024 | 
insideprecisionmedicine.com | Larissa Warneck
Researchers at the University College London (UCL) and UCL Great Ormond Street Institute of Child Health have developed a novel immunotherapeutic platform technology that uses engineered T cells to attack bone cancer cells and activate other cancer-fighting immune cells to do the same. The researchers aimed to overcome different challenges that current immunotherapies have in treating solid tumors.
-
May 3, 2024 | 
insideprecisionmedicine.com | Larissa Warneck
Researchers at the Medical College of Georgia (MCG) have found that targeting a specific receptor in the eye may benefit many patients with neovascular age-related macular degeneration, who don’t respond well to current treatments. Age-related macular degeneration is a leading cause of blindness worldwide and occurs mostly in the elderly and people with metabolic diseases, such as diabetes and obesity.
